MyoKardia (MYOK) Re-acquires Global Rights to Mavacamten and MYK-491 Programs from Sanofi (SNY)

January 2, 2019 8:13 AM

MyoKardia, Inc. (NASDAQ: MYOK) today announced it has regained worldwide rights to all programs covered under its license and collaboration ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found